1. Blaker D, Detsky A, Hubbard E, Kennedy W, Konchak R, Menon D, et al. Guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop on Pharmacoeconomics Steering Committee. Sainte-Adèle, Québec, Canada. 1994. p. 1–38.
2. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146(4):473–91.
3. Aristides M, Mitchell A. Applying the Australian guidelines for the reimbursement of pharmaceuticals. Pharmacoeconomics. 1994;6(3):196–201.
4. Taylor RS, Drummond MF, Salkeld G, Sullivan SD. Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle. BMJ. 2004;329(7472):972–5.
5. Ungar WJ. Paediatric health economic evaluations: a world view. Healthc Q. 2006;10(1):134–40, 42–45.